Caribou Biosciences, Inc. (CRBU): who owns it and who trades it
As of Nov 16, 2026, CRBU insiders reported 4 open-market sales worth $33.9K and no purchases in the last 12 months, with 6% of the sale value made under pre-set 10b5-1 plans. The largest seller was Timothy P Kelly (Chief Technology Officer), with $18.2K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Caribou Biosciences
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CRBU
137 funds and institutions reported CRBU shares worth $86.8M at the end of Q2 2026, about 50% of the company. The largest holder is BlackRock, Inc. with 7.9%.
Funds and institutions (13F) 50%Everyone else 50%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 7.82M | 7.88% | $13.8M | +265% |
| Pfizer Inc | 4.69M | 4.73% | $7.9M | No change |
| Vanguard Capital Management LLC | 4.21M | 4.24% | $7.4M | +12% |
| Mackenzie Financial Corp | 3.65M | 3.68% | $6.4M | +287% |
| Renaissance Technologies LLC | 2.77M | 2.80% | $4.9M | +7% |
| Kynam Capital Management, LP | 2.50M | 2.52% | $4.4M | No change |
| Geode Capital Management, LLC | 2.37M | 2.39% | $4.2M | +133% |
| Acadian Asset Management LLC | 1.77M | 1.79% | $3.1M | +92% |
| State Street Corp | 1.63M | 1.65% | $2.9M | +286% |
| Bank of America Corp | 1.41M | 1.42% | $2.5M | +9% |
| Two Sigma Investments, LP | 1.05M | 1.05% | $1.8M | -41% |
| Dimensional Fund Advisors LP | 975,327 | 0.98% | $1.7M | +45% |
| Charles Schwab Investment Management Inc | 775,809 | 0.78% | $1.4M | +39% |
| Sixth Street Partners Management Company, L.P. | 775,809 | 0.78% | $1.4M | – |
| Cambridge Investment Research Advisors, Inc. | 764,820 | 0.77% | $1.3M | +40% |
| FMR LLC (Fidelity) | 727,115 | 0.73% | $1.3M | +0% |
| Northern Trust Corp | 712,965 | 0.72% | $1.3M | +227% |
| Maverick Capital Ltd | 652,542 | 0.66% | $1.1M | No change |
| Vanguard Portfolio Management LLC | 613,801 | 0.62% | $1.1M | – |
| Vanguard Fiduciary Trust Co | 606,388 | 0.61% | $1.1M | +17% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CRBU insiders reported $0 of open-market purchases and $33.9K of sales. 6% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | Timothy P Kelly | Chief Technology Officer | Sale | 6,228 | $1.93 | $12K | Form 4 |
| Feb 24, 2026 | Timothy P Kelly | Chief Technology Officer | Sale | 3,147 | $1.96 | $6.2K | Form 4 |
| Feb 24, 2026 | Barbara G Mcclung | Chief Legal Officer | Sale | 6,938 | $1.96 | $13.6K | Form 4 |
| Feb 24, 2026 | Tina M. Albertson | Chief Medical Officer | Sale plan | 1,066 | $1.96 | $2.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Timothy P Kelly | Chief Technology Officer | – | $18.2K | Feb 25, 2026 |
| Barbara G Mcclung | Chief Legal Officer | – | $13.6K | Feb 24, 2026 |
| Tina M. Albertson | Chief Medical Officer | – | $2.1K | Feb 24, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CRBU short interest
High short interest. 13.9% of CRBU shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 109%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 14.89M CRBU shares were sold short, 13.9% of the shares outstanding, up 18.6% from the report before. At the average daily volume of 2.47M shares, buying them all back would take about 6.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 14.89M | 13.89% | +19% | 2.47M | 6.0 |
| Oct 15, 2026 | 12.55M | 11.71% | -3% | 8.14M | 1.5 |
| Sep 30, 2026 | 12.91M | 12.05% | -0% | 986,415 | 13.1 |
| Sep 15, 2026 | 12.98M | 12.11% | +4% | 1.37M | 9.5 |
| Aug 31, 2026 | 12.50M | 11.66% | +0% | 966,397 | 12.9 |
| Aug 14, 2026 | 12.47M | 11.63% | +7% | 1.04M | 11.9 |
| Jul 31, 2026 | 11.64M | 11.74% | +0% | 1.24M | 9.4 |
| Jul 15, 2026 | 11.59M | 11.69% | +20% | 2.36M | 4.9 |
| Jun 30, 2026 | 9.63M | 9.71% | +28% | 3.16M | 3.0 |
| Jun 15, 2026 | 7.53M | 7.59% | +1% | 1.82M | 4.2 |
| May 29, 2026 | 7.45M | 7.51% | +4% | 1.84M | 4.0 |
| May 15, 2026 | 7.14M | 7.20% | +0% | 1.58M | 4.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Caribou Biosciences company events
Caribou Biosciences filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 6, 2026LeadershipThe employment of Sriram Ryali, the Company’s Chief Financial Officer, will terminate on the date the Company executes a binding definitive agreement for a strategic alternative, and such termination would be treated as a termination “without cause” under the Employment Agreement, dated January 2… Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- Jun 11, 2026AnnouncementThe Company announced long-term follow-up data from its ANTLER phase 1 clinical trial that evaluated vispa-cel, an off-the-shelf CD19-targeted CAR-T cell therapy product candidate, in patients with r/r B-NHL. The Company also announced longer follow-up data from the dose escalation portion of its… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 31, 2026AnnouncementThe Company announced that it received RMAT designation for r/r MM from the FDA for CB-011, its allogeneic anti-BCMA CAR-T cell therapy product candidate. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Caribou Biosciences financials
Famous investors that hold CRBU
3 of the 50 well-known investors we track reported holding CRBU in their latest 13F filing. The largest position is Jim Simons's, worth $3.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.56M | $3.2M | 0.0% | -8% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 652,542 | $829K | 0.0% | No change |
| Ken Griffin · Citadel Advisors | Q3 2026 | 107,367 | $136K | 0.0% | +166% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Caribou Biosciences, Inc. (CRBU) stock
Who owns the most CRBU stock?
The largest reported owner of Caribou Biosciences, Inc. (CRBU) is BlackRock, Inc., with 7.9% of the company. In total, 137 funds and institutions reported holding CRBU at the end of Q2 2026, together about 50% of the shares. See the largest owners.
Are CRBU insiders buying or selling?
In the last 12 months, CRBU insiders reported no open-market purchases and 4 sales worth $33.9K. The latest trade was on Feb 25, 2026. See every trade.
What is the short interest in CRBU?
As of Oct 30, 2026, 14.89M CRBU shares were sold short, 13.9% of the shares outstanding, up 18.6% from the report before. At the average daily volume of 2.47M shares, buying them all back would take about 6.0 trading days (days to cover). See the history.
Which famous investors hold CRBU?
3 of the 50 well-known investors we track reported CRBU in their latest 13F filing, including Jim Simons, Lee Ainslie, Ken Griffin. The largest position is worth $3.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.